• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Fluidigm Corporation

    4/14/22 5:09:34 PM ET
    $FLDM
    Biotechnology: Laboratory Analytical Instruments
    Capital Goods
    Get the next $FLDM alert in real time by email
    SC 13G 1 efc22-240_sc13g.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d-
    1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934*
     
    Standard BioTools Inc.
    (Name of Issuer)
     
    Common stock, $0.001 par value per share
    (Title of Class of Securities)
     
    34385P108
    (CUSIP Number)
     
    April 4, 2022
    (Date of Event Which Requires Filing of this Statement)
     

     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    CUSIP No. 74276L105
    13G
    Page 2 of 22 Pages

     
    1
    NAME OF REPORTING PERSON

    Viking Global Investors LP
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    8,103,527*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    8,103,527*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,103,527*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.5%*
    12
    TYPE OF REPORTING PERSON

    PN
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 3 of 22 Pages

    1
    NAME OF REPORTING PERSON

    Viking Global Opportunities Parent GP LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    8,103,527*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    8,103,527*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,103,527*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.5%*
    12
    TYPE OF REPORTING PERSON

    OO
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 4 of 22 Pages

    1
    NAME OF REPORTING PERSON

    Viking Global Opportunities GP LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    5,429,410*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    5,429,410*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,429,410*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.4%*
    12
    TYPE OF REPORTING PERSON

    OO
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 5 of 22 Pages

    1
    NAME OF REPORTING PERSON

    Viking Global Opportunities Portfolio GP LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    5,429,410*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    5,429,410*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,429,410*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.4%*
    12
    TYPE OF REPORTING PERSON

    OO
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 6 of 22 Pages

    1
    NAME OF REPORTING PERSON

    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    5,429,410*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    5,429,410*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,429,410*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.4%*
    12
    TYPE OF REPORTING PERSON*

    PN
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 7 of 22 Pages

    1
    NAME OF REPORTING PERSON
     
    Viking Global Opportunities Drawdown GP LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    2,674,117*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    2,674,117*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,674,117*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.1%*
    12
    TYPE OF REPORTING PERSON

    OO
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 8 of 22 Pages


    1
    NAME OF REPORTING PERSON
     
    Viking Global Opportunities Drawdown Portfolio GP LLC
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    2,674,117*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    2,674,117*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,674,117*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.1%*
    12
    TYPE OF REPORTING PERSON

    OO
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 9 of 22 Pages

    1
    NAME OF REPORTING PERSON
     
    Viking Global Opportunities Drawdown (Aggregator) LP
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    2,674,117*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    2,674,117*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,674,117*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    3.1%*
    12
    TYPE OF REPORTING PERSON

    OO
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 10 of 22 Pages

    1
    NAME OF REPORTING PERSON

    O. Andreas Halvorsen
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    Norway
     


    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    8,103,527*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    8,103,527*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,103,527*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.5%*
    12
    TYPE OF REPORTING PERSON*

    IN
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 11 of 22 Pages

    1
    NAME OF REPORTING PERSON

    David C. Ott
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    8,103,527*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    8,103,527*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,103,527*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.5%*
    12
    TYPE OF REPORTING PERSON*

    IN
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 12 of 22 Pages

    1
    NAME OF REPORTING PERSON

    Rose S. Shabet
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a) ☐
    (b) ☒
    3
    SEC USE ONLY
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER

    0
    6
    SHARED VOTING POWER

    8,103,527*
    7
    SOLE DISPOSITIVE POWER

    0
    8
    SHARED DISPOSITIVE POWER

    8,103,527*
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    8,103,527*
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.5%*
    12
    TYPE OF REPORTING PERSON*

    IN
               
    * See Item 4

    CUSIP No. 74276L105
    13G
    Page 13 of 22 Pages

    Item 1(a).
    Name of Issuer:

    Standard BioTools Inc.

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    2 Tower Place, Suite 2000, South San Francisco, CA 94080

    Item 2(a).
    Name of Person Filing:

    Viking Global Investors LP (“VGI”),
    Viking Global Opportunities Parent GP LLC (“Opportunities Parent”),
    Viking Global Opportunities GP LLC (“Opportunities GP”),
    Viking Global Opportunities Portfolio GP LLC (“Opportunities Portfolio GP”),
    Viking Global Opportunities Illiquid Investments Sub-Master LP (“VGOP”),
    Viking Global Opportunities Drawdown GP LLC (“VGOD GP”),
    Viking Global Opportunities Drawdown Portfolio GP LLC (“VGOD Portfolio GP”),
    Viking Global Opportunities Drawdown (Aggregator) LP (“VGOD”),
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet (collectively, the “Reporting Persons”).

    Item 2(b).
    Address of Principal Business Office or, if none, Residence:

    The business address of each of the Reporting Persons is: 55 Railroad Avenue, Greenwich, Connecticut 06830.

    Item 2(c).
    Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOD GP, and VGOD Portfolio GP are Delaware limited liability companies; VGOP and VGOD are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.

    Item 2(d).
    Titles of Classes of Securities:

    Common stock, $0.001 par value per share (“Common Stock”)

    Item 2(e).
    CUSIP NUMBER: 34385P108

    Item 3.
    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:


    (a)
    ☐ Broker or dealer registered under Section 15 of the Exchange Act


    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Exchange Act


    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act


    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940


    (e)
    ☐ Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940: see Rule 13d-1(b)(1)(ii)(E)


    CUSIP No. 74276L105
    13G
    Page 14 of 22 Pages



    (f)
    ☐ Employee Benefit Plan, Pension Fund which is subject to the provisions of the Employee Retirement Income Security Act of 1974 or Endowment Fund; see Rule 13d-1(b)(1)(ii)(F)


    (g)
    ☐ Parent holding company, in accordance with Rule 13d-1(b)(1)(ii)(G).


    (h)
    ☐ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act.


    (i)
    ☐ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.


    (j)
    ☐ Non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership:

    This Statement on Schedule 13G relates to shares of Common Stock that the Reporting Persons have the right to acquire upon conversion of shares of Series B-2 Preferred Stock (“Series B-2 Preferred Stock”) held directly by VGOP and VGOD.  VGOP owns 85,612 shares of Series B-2 Preferred Stock and VGOD owns 42,167 shares of Series B-2 Preferred Stock, and the Series B-2 Preferred Stock has an initial conversion rate of 294.1176 shares of Common Stock per share of Series B-2 Preferred Stock.  However, the Certificate of Designation for the Series B-2 Preferred Stock provides that none of VGOP, VGOD, nor their affiliates shall be entitled to convert shares of Series B-2 Preferred Stock unless such conversion would not result in VGOP and VGOD, together with their affiliates, beneficially owning more than 9.5% of the total number of shares of Common Stock outstanding (the “Blocker”).  Accordingly, the amount of shares of Common Stock reported as beneficially owned by the Reporting Persons set forth herein excludes shares of Common Stock that the Reporting Persons do not currently have the right to acquire upon conversion of the Series B-2 Preferred Stock held directly by VGOP and VGOD due to the Blocker (and applies the Blocker pro rata across VGOP and VGOD). Without giving effect to the 9.5% blocker provision, the Series B-2 Preferred Stock held by VGOP would be convertible into 25,179,995 shares of Common Stock and the Series B-2 Preferred Stock held by VGOD would be convertible into 12,402,056 shares of Common Stock, for an aggregate of 37,582,051 shares of Common Stock.

    The percentages set forth herein are calculated based on (i) 77,198,577 shares of Common Stock outstanding as of February 28, 2022, as reported in the Company’s Form 10-K filed with the Commission on March 8, 2022, and (ii) 8,103,527 shares of Common Stock that the Reporting Persons currently have the right to acquire upon conversion of the Series B Preferred Stock, subject to the Blocker.


    A.
    VGI


    (a)
    Amount beneficially owned: 8,103,527


    (b)
    Percent of Class: 9.5%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 8,103,527


    CUSIP No. 74276L105
    13G
    Page 15 of 22 Pages



    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 8,103,527

    VGI provides managerial services to VGOP and VGOD. VGI has the authority to dispose of and vote the shares of Common Stock that VGOP and VGOD have the right to acquire upon conversion of the Series B-2 Preferred Stock.  VGI does not directly own any shares of Common Stock or Series B-2 Preferred Stock.

    Based on Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the “Act”), VGI may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD have the right to acquire upon conversion of the Series B-2 Preferred Stock.

    VGI beneficially owns 8,103,527 shares of Common Stock consisting of (i) 5,429,410 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to acquire upon conversion of 18,460 shares of Series B-2 Preferred Stock, and (ii) 2,674,117 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to acquire upon conversion of 9,092 shares of Series B-2 Preferred Stock, each subject to the Blocker.


    B.
    Opportunities Parent


    (a)
    Amount beneficially owned: 8,103,527
     

    (b)
    Percent of Class: 9.5%
     

    (c)
    Number of shares as to which such person has:
     

    (i)
    Sole power to vote or to direct the vote: 0
     

    (ii)
    Shared power to vote or to direct the vote: 8,103,527
     

    (iii)
    Sole power to dispose or to direct the disposition of: 0
     

    (iv)
    Shared power to dispose or to direct the disposition of: 8,103,527
     
    Opportunities Parent is the general partner of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP (which consists of the shares of Common Stock that VGOP has the right to acquire upon conversion of the Series B-2 Preferred Stock) and is the general partner of VGOD GP, which has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP (which consists of the shares of Common Stock that VGOD has the right to acquire upon conversion of the Series B-2 Preferred Stock). Opportunities Parent does not directly own any shares of Common Stock or Series B-2 Preferred Stock.
     
    Based on Rule 13d-3 of the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD have the right to acquire upon conversion of the Series B-2 Preferred Stock.

    Opportunities Parent beneficially owns 8,103,527 shares of Common Stock consisting of (i) 5,429,410 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to acquire upon conversion of 18,460 shares of Series B-2 Preferred Stock, and (ii) 2,674,117 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to acquire upon conversion of 9,092 shares of Series B-2 Preferred Stock, each subject to the Blocker.

    CUSIP No. 74276L105
    13G
    Page 16 of 22 Pages



    C.
    Opportunities GP


    (a)
    Amount beneficially owned: 5,429,410


    (b)
    Percent of Class: 6.4%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 5,429,410


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 5,429,410


    Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP has the right to acquire upon conversion of the Series B-2 Preferred Stock. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. Opportunities GP does not directly own any shares of Common Stock or Series B-2 Preferred Stock.

    Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOP has the right to acquire upon conversion of the Series B-2 Preferred Stock.

    Opportunities GP beneficially owns 5,429,410 shares of Common Stock consisting of 5,429,410 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to acquire upon conversion of 18,460 shares of Series B-2 Preferred Stock.


    D.
    Opportunities Portfolio GP


    (a)
    Amount beneficially owned: 5,429,410


    (b)
    Percent of Class: 6.4%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 5,429,410


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 5,429,410

    Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP has the right to acquire upon conversion of the Series B-2 Preferred Stock. Opportunities Portfolio GP does not directly own any shares of Common Stock or Series B-2 Preferred Stock.

    CUSIP No. 74276L105
    13G
    Page 17 of 22 Pages


    Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP has the right to acquire upon conversion of the Series B-2 Preferred Stock.

    Opportunities Portfolio GP beneficially owns 5,429,410 shares of Common Stock consisting of 5,429,410 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to acquire upon conversion of 18,460 shares of Series B-2 Preferred Stock.


    E.
    VGOP


    (a)
    Amount beneficially owned: 5,429,410


    (b)
    Percent of Class: 6.4%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 5,429,410


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 5,429,410

    VGOP has the authority to dispose of and vote the shares of Common Stock that it has the right to acquire upon conversion of the Series B-2 Preferred Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP.

    Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP.


    F.
    VGOD GP


    (a)
    Amount beneficially owned: 2,674,117


    (b)
    Percent of Class: 3.1%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 2,674,117


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    CUSIP No. 74276L105
    13G
    Page 18 of 22 Pages


    (iv)
    Shared power to dispose or to direct the disposition of: 2,674,117

    VGOD GP serves as the sole member of VGOD Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by VGOD Portfolio GP, which consists of the shares of Common Stock that VGOD has the right to acquire upon conversion of the Series B-2 Preferred Stock. In addition, VGOD GP is the general partner of each of Viking Global Opportunities (Internal) LP, Viking Global Opportunities Drawdown (Onshore) LP, and Viking Global Opportunities Drawdown (Offshore) LP. VGOD GP does not directly own any shares of Common Stock or Series B-2 Preferred Stock.
     
    Based on Rule 13d-3 of the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOD has the right to acquire upon conversion of the Series B-2 Preferred Stock.
     
    VGOD GP beneficially owns 2,674,117 shares of Common Stock consisting of 2,674,117 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to acquire upon conversion of 9,092 shares of Series B-2 Preferred Stock, each subject to the Blocker.
     

    G.
    VGOD Portfolio GP


    (a)
    Amount beneficially owned: 2,674,117


    (b)
    Percent of Class: 3.1%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 2,674,117


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 2,674,117

    VGOD Portfolio GP serves as the general partner of VGOD and has the authority to dispose of and vote the shares of Common Stock that VGOD has the right to acquire upon conversion of the Series B-2 Preferred Stock. VGOD Portfolio GP does not directly own any shares of Common Stock or Series B-2 Preferred Stock.
     
    Based on Rule 13d-3 of the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOD has the right to acquire upon conversion of the Series B-2 Preferred Stock.
     
    VGOD Portfolio GP beneficially owns 2,674,117 shares of Common Stock consisting of 2,674,117 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to acquire upon conversion of 9,092 shares of Series B-2 Preferred Stock, each subject to the Blocker.
     

    H.
    VGOD


    (a)
    Amount beneficially owned: 2,674,117


    CUSIP No. 74276L105
    13G
    Page 19 of 22 Pages



    (b)
    Percent of Class: 3.1%


    (c)
    Number of shares as to which such person has:


    (i)
    Sole power to vote or to direct the vote: 0


    (ii)
    Shared power to vote or to direct the vote: 2,674,117


    (iii)
    Sole power to dispose or to direct the disposition of: 0


    (iv)
    Shared power to dispose or to direct the disposition of: 2,674,117

    VGOD has the authority to dispose of and vote the shares of Common Stock that it has the right to acquire upon conversion of the Series B-2 Preferred Stock directly owned by it, which power may be exercised by VGOD Portfolio GP, and by VGI, an affiliate of VGOD Portfolio GP, which provides managerial services to VGOD.
     
    Viking Global Opportunities Drawdown (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Drawdown (Internal) LP (a Delaware limited partnership), through its investment in Viking Global Opportunities Drawdown (Onshore) LP (a Delaware limited partnership), invest substantially all of their assets in VGOD.
     

    I.
    O. Andreas Halvorsen, David C. Ott and Rose S. Shabet
     

    (a)
    Amount beneficially owned: 8,103,527
     

    (b)
    Percent of Class: 9.5%
     

    (c)
    Number of shares as to which such person has:
     

    (i)
    Sole power to vote or to direct the vote: 0
     

    (ii)
    Shared power to vote or to direct the vote: 8,103,527
     

    (iii)
    Sole power to dispose or to direct the disposition of: 0
     

    (iv)
    Shared power to dispose or to direct the disposition of: 8,103,527
     
    Mr. Halvorsen, Mr. Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. None of Mr. Halvorsen, Mr. Ott and Ms. Shabet directly owns any shares of Common Stock or Series B-2 Preferred Stock.
     
    Based on Rule 13d-3 of the Act, each may be deemed to beneficially own the shares of Common Stock that VGOP and VGOD have the right to acquire upon conversion of the Series B-2 Preferred Stock.
     
    Mr. Halvorsen, Mr. Ott and Ms. Shabet each beneficially own 8,103,527 shares of Common Stock consisting of (i) 5,429,410 shares of Common Stock beneficially owned by VGOP, which VGOP has the right to acquire upon conversion of 18,460 shares of Series B-2 Preferred Stock, and (ii) 2,674,117 shares of Common Stock beneficially owned by VGOD, which VGOD has the right to acquire upon conversion of 9,092 shares of Series B-2 Preferred Stock, each subject to the Blocker.

    CUSIP No. 74276L105
    13G
    Page 20 of 22 Pages

     
    Item 5.
    Ownership of Five Percent or Less of a Class.
     
    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    The response to Item 4 is incorporated by reference herein.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.
     
    Item 10.
    Certification. (if filing pursuant to Rule 13d-1(c))
     
    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and not held in connection with or as a participant in any transaction having that purpose or effect.
     

    CUSIP No. 74276L105
    13G
    Page 21 of 22 Pages

    SIGNATURES
     
    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.
     
    Dated: April 14, 2022
     
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)

     
    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
     

    CUSIP No. 74276L105
    13G
    Page 22 of 22 Pages

    EXHIBIT A - JOINT FILING AGREEMENT
     
    This joint filing agreement is made and entered into as of this 14th day of April, 2022, by and among Viking Global Investors LP, Viking Global Opportunities Parent GP LLC, Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, Viking Global Opportunities Drawdown GP LLC, Viking Global Opportunities Drawdown Portfolio GP LLC, Viking Global Opportunities Drawdown (Aggregator) LP, O. Andreas Halvorsen, David C. Ott and Rose S. Shabet.
     
    The parties to this Agreement hereby agree to prepare jointly and file timely (and otherwise to deliver as appropriate) all filings on any Forms 3, 4, or 5 or Schedules 13D or 13G, and any and all amendments thereto and any other documents relating thereto (collectively, the “Filings”) as required to be filed pursuant to the Securities Exchange Act of 1934, as amended. The parties to this Agreement further agree and covenant that each will fully cooperate with such other parties in the preparation, timely filing, and delivery of all such Filings.
     
    IN WITNESS WHEREOF, the parties hereto have executed this agreement as of the date first set forth above.
     
    Dated: April 14, 2022
     
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of David C. Ott (2)
       
     
    By:
    /s/ Scott M. Hendler
     
     
    Name:
    Scott M. Hendler on behalf of Rose S. Shabet (3)


    (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES DRAWDOWN GP LLC, VIKING GLOBAL OPPORTUNITIES DRAWDOWN PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES DRAWDOWN (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
     
    Get the next $FLDM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $FLDM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FLDM
    SEC Filings

    See more
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      7/7/22 4:00:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Leadership Update

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/27/22 4:04:35 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - STANDARD BIOTOOLS INC. (0001162194) (Filer)

      6/16/22 2:06:26 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $FLDM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $FLDM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Standard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SOUTH SAN FRANCISCO, Calif., April 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (f/k/a Fluidigm Corporation) (NASDAQ:FLDM) today announced, as required by Nasdaq Stock Market Rules, the grant of equity inducement awards to its new executive officers Michael Egholm, the Company's new President, Chief Executive Officer and a member of the Company's Board of Directors, and Hanjoon (Alex) Kim, the Company's new Chief Operating Officer, and a new employee, Ardalan (Alex) Arfaei, the Company's new Senior Vice President, Corporate Development. In accordance with Nasdaq Listing Rule 5635(c)(4), Standard BioTools' Compensation Committee of its Board of Directors, which is composed entirely

      4/5/22 7:15:24 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

      SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Dr. Carlos V. Paya, chairman of Fluidigm, said, "On behalf of the Board of Directors, I would like to thank our stockholders for their support of this investment, which is expected to fuel a realization of identified growth and cost opportunities within the Company's two major platforms, mass cytometry and microfluidics, and pave the way

      4/1/22 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Piper Sandler reiterated coverage on Fluidigm with a new price target

      Piper Sandler reiterated coverage of Fluidigm with a rating of and set a new price target of $8.00 from $15.00 previously

      2/11/21 12:35:14 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:11:15 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:06:21 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units

      4 - STANDARD BIOTOOLS INC. (0001162194) (Issuer)

      6/17/22 6:05:59 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Leadership Updates

    Live Leadership Updates

    See more
    • Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

      New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022 Appoints New Management Team and Additional Board Members with Significant Experience to Reinvigorate Growth and Enhance Product Portfolio Embarks on New Chapter of Focused Execution and Growth SOUTH SAN FRANCISCO, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the closing of the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC ("Casdin") and Viking Global Investors LP ("Viking"). Fluidigm has been renamed Standard BioTools Inc. ("Standard BioTools") and its common stock is expected to begin trading on Nasdaq under

      4/4/22 5:30:57 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

      Caligan Partners to Vote "FOR" Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022 Fluidigm Board to Appoint Frank Witney, a Director Candidate Recommended by Caligan, if Casdin and Viking Transaction Closes Company Urges ALL Stockholders to Vote "FOR" the Proposals at the Special Meeting SOUTH SAN FRANCISCO, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it has entered into a support agreement with Caligan Partners LP ("Caligan"), Fluidigm's current largest holder of common stock, under which Caligan has agreed to vote "FOR" all Fluidigm proposals related to the

      3/29/22 9:29:06 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

      SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem in South San Francisco and appointed Gajus Worthington to its Board of Directors. The Company is now positioned to accelerate the translation of its proprietary cf-mRNA Liquid Biopsy Technology Platform to develop products and services for Precision Medicine clinical practice and biopharma R&D. "We

      1/4/22 6:00:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Financials

    Live finance-specific insights

    See more
    • Fluidigm Announces Third Quarter 2021 Financial Results

      Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the third quarter ended September 30, 2021. "We saw a very active third quarter and made progress with our ambitious plan to commercially scale two new instrument systems," said Chris Linthwaite, President and CEO. "Core demand for our products was healthy, but we were unable to fulfill all orders for our products during the quarter, largely due to supply chain issues. Our b

      11/8/21 4:02:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

      SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on November 8, 2021, to discuss third quarter 2021 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call. Individuals int

      10/20/21 8:30:00 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million

      Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the second quarter ended June 30, 2021. "Second quarter results were driven by a rebound in our base business and early customer orders following the launch of our new fourth generation CyTOF® XT mass cytometry product," said Chris Linthwaite, President and CEO. "Our services busines

      8/5/21 4:05:00 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods

    $FLDM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      6/7/22 10:31:54 AM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13D/A filed by Fluidigm Corporation (Amendment)

      SC 13D/A - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      5/3/22 12:40:48 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods
    • SEC Form SC 13G filed by Fluidigm Corporation

      SC 13G - STANDARD BIOTOOLS INC. (0001162194) (Subject)

      4/14/22 5:09:34 PM ET
      $FLDM
      Biotechnology: Laboratory Analytical Instruments
      Capital Goods